A recently published study in JAMA sought to determine if there is a link between acetaminophen use during pregnancy and children’s risk of developing autism, ADHD, or intellectual disabilities.
A newly published study has found that there is no link between acetaminophen use during pregnancy and the risk of children developing a neurodevelopmental disorder, despite a previous consensus statement cautioning its use during pregnancy.1
Acetaminophen is one of the most commonly used drugs for managing pain and fever in pregnancy, with both the FDA and European Medicines Agency deeming the drug to pose minimal risk when used during pregnancy.2,3
However, a 2021 consensus statement supported by 91 scientists, clinicians, and public health professionals, cautioned the use of paracetamol (N-acetyl-p-aminophenol [APAP] or acetaminophen) during pregnancy, citing “increasing experimental and epidemiological research suggests that prenatal exposure to APAP might alter fetal development, which could increase the risks of some neurodevelopmental, reproductive, and urogenital disorders.”4
A recently published JAMA study sought to investigate the use of acetaminophen during pregnancy and the risk of autism, attention-deficit/hyperactivity disorder (ADHD), and intellectual disability in approximately 2.5 million children in Sweden from 1995 to 2019.1
Results of the analysis showed 7.49% (n = 185,909) of children were exposed to acetaminophen during pregnancy. Also, crude absolute risks at 10 years for children not exposed vs children exposed to acetaminophen were 1.33% vs 1.53% for autism, 2.46% vs 2.87% for ADHD, and 0.70% vs 0.82% for intellectual disability.1
Additionally, in models without sibling control, ever-use vs no use of acetaminophen during pregnancy was associated with a slightly increased risk of autism (hazard ratio [HR], 1.05 [95%CI, 1.02-1.08]; risk difference [RD] at 10 years of age, 0.09% [95%CI, −0.01% to 0.20%]), ADHD (HR, 1.07 [95%CI, 1.05-1.10]; RD, 0.21% [95%CI, 0.08%-0.34%]), and intellectual disability (HR, 1.05 [95%CI, 1.00-1.10]; RD, 0.04%[95%CI, −0.04%to 0.12%]).1
Matched full sibling pairs were also analyzed to address unobserved confounding, according to the authors. Further results showed that sibling control analyses found no evidence that acetaminophen use during pregnancy was linked with autism (HR, 0.98 [95%CI, 0.93-1.04]; RD, 0.02%[95%CI, −0.14%to 0.18%]), ADHD (HR, 0.98 [95%CI, 0.94-1.02]; RD, −0.02%[95%CI, −0.21% to 0.15%]), or intellectual disability (HR, 1.01 [95%CI, 0.92-1.10]; RD, 0%[95%CI, −0.10% to 0.13%]).1
“This study’s findings may be welcome news for birthing people who use acetaminophen as a pain or fever management option since there are few safe alternatives for relief available,” said investigator Renee M. Gardner, PhD, Karolinska Institutet.5 “We hope that our results provide reassurance to expectant parents when faced with the sometimes fraught decision of whether to take these medications during pregnancy when suffering from pain or fever.”
References:
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Identifying gaps in syphilis treatment and prenatal care among pregnant individuals
May 17th 2024Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.
Read More
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More